AstraZeneca sets floor price for delisting of Indian arm
This article was originally published in Scrip
Executive Summary
AstraZeneca Pharmaceuticals AB has set a floor price of Rs576.10 ($12.30) per share to acquire the residual 10% free float in its Indian arm, AstraZeneca Pharma India, as part of a delisting offer.